CARLSBAD, Calif., May 26 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a general corporate update in conjunction with its 2010 Annual Meeting of Stockholders and Open House on June 2 from 2:00 p.m. to 6:00 p.m. Pacific Time in Carlsbad, CA.
The agenda for the meeting is as follows:
2:00 p.m. 2:15 p.m. Annual Meeting of Stockholders (stockholders of record as of April 6, 2010 only)
2:15 p.m. 2:45 p.m. Corporate Presentation Stanley T. Crooke, Chairman and CEO, Isis
2:45 p.m. 3:00 p.m. Mipomersen Commercialization Presentation John Butler, Genzyme
The agenda for the scientific session is as follows:
3:00 p.m. 4:00 p.m. Mipomersen Lipid-Expert Panel Discussion
4:00 p.m. 6:00 p.m. Poster Presentation
The mipomersen panel will be comprised of three renowned physicians: Dr. William Cromwell, Dr. Willis Maddrey and Dr. Joseph Witztum and moderated by Dr. Bruce Turner, healthcare fund manager at Bank of America. Questions for the panelists may be submitted through Isis’ Company Web site, www.isispharm.com, in advance of the meeting.
A live audio webcast of the presentations will be available on the “Investors & Media” section of the Company’s Web site, www.isispharm.com. A replay of the presentations will be available on the Isis Web site within 48 hours and will be archived for a limited time.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world’s first antisense drug and has 22 drugs in development. Isis’ drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. Isis’ partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.
SOURCE Isis Pharmaceuticals, Inc.
